MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07463521 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-17

No results posted yet for this study

Summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.

Conditions

  • Ocular Myasthenia Gravis

Interventions

DRUG

Rozanolixizumab

Rozanolixizumab will be administered by subcutaneous infusion.

DRUG

Placebo

Placebo will be administered by subcutaneous infusion.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-29
Primary Completion
2028-12-01
Completion
2029-01-22
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07463521 on ClinicalTrials.gov